These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

214 related articles for article (PubMed ID: 28011910)

  • 21. Analysis of the vaccine-induced influenza B virus hemagglutinin-specific antibody dependent cellular cytotoxicity response.
    de Vries RD; Nieuwkoop NJ; Krammer F; Hu B; Rimmelzwaan GF
    Virus Res; 2020 Feb; 277():197839. PubMed ID: 31837382
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Influenza Virus Hemagglutinin Stalk-Specific Antibodies in Human Serum are a Surrogate Marker for
    Jacobsen H; Rajendran M; Choi A; Sjursen H; Brokstad KA; Cox RJ; Palese P; Krammer F; Nachbagauer R
    mBio; 2017 Sep; 8(5):. PubMed ID: 28928215
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Influenza Virus Infection Enhances Antibody-Mediated NK Cell Functions via Type I Interferon-Dependent Pathways.
    Jegaskanda S; Vanderven HA; Tan HX; Alcantara S; Wragg KM; Parsons MS; Chung AW; Juno JA; Kent SJ
    J Virol; 2019 Mar; 93(5):. PubMed ID: 30541850
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Measuring influenza hemagglutinin (HA) stem-specific antibody-dependent cellular cytotoxicity (ADCC) in human sera using novel stabilized stem nanoparticle probes.
    Smatti MK; Nasrallah GK; Al Thani AA; Yassine HM
    Vaccine; 2020 Jan; 38(4):815-821. PubMed ID: 31735504
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Vaccination with 2014-15 Seasonal Inactivated Influenza Vaccine Elicits Cross-Reactive Anti-HA Antibodies with Strong ADCC Against Antigenically Drifted Circulating H3N2 Virus in Humans.
    Zhong W; Gross FL; Holiday C; Jefferson SN; Bai Y; Liu F; Katz JM; Levine MZ
    Viral Immunol; 2016 May; 29(4):259-62. PubMed ID: 26950058
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A recombinant H7N9 influenza vaccine with the H7 hemagglutinin transmembrane domain replaced by the H3 domain induces increased cross-reactive antibodies and improved interclade protection in mice.
    Wang Y; Wu J; Xue C; Wu Z; Lin Y; Wei Y; Wei X; Qin J; Zhang Y; Wen Z; Chen L; Liu GD; Cao Y
    Antiviral Res; 2017 Jul; 143():97-105. PubMed ID: 28408133
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Cross-reactive influenza-specific antibody-dependent cellular cytotoxicity-mediating antibodies in HIV-infected Indian individuals.
    Nehul S; Kulkarni A; Pawar S; Godbole S; Ghate M; Thakar M
    Infect Dis (Lond); 2018 Jan; 50(1):35-43. PubMed ID: 28776433
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Antibody Landscape Analysis following Influenza Vaccination and Natural Infection in Humans with a High-Throughput Multiplex Influenza Antibody Detection Assay.
    Li ZN; Liu F; Gross FL; Kim L; Ferdinands J; Carney P; Chang J; Stevens J; Tumpey T; Levine MZ
    mBio; 2021 Feb; 12(1):. PubMed ID: 33531397
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Standard trivalent influenza virus protein vaccination does not prime antibody-dependent cellular cytotoxicity in macaques.
    Jegaskanda S; Amarasena TH; Laurie KL; Tan HX; Butler J; Parsons MS; Alcantara S; Petravic J; Davenport MP; Hurt AC; Reading PC; Kent SJ
    J Virol; 2013 Dec; 87(24):13706-18. PubMed ID: 24109221
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Relationship of preexisting influenza hemagglutination inhibition, complement-dependent lytic, and antibody-dependent cellular cytotoxicity antibodies to the development of clinical illness in a prospective study of A(H1N1)pdm09 Influenza in children.
    Co MD; Terajima M; Thomas SJ; Jarman RG; Rungrojcharoenkit K; Fernandez S; Yoon IK; Buddhari D; Cruz J; Ennis FA
    Viral Immunol; 2014 Oct; 27(8):375-82. PubMed ID: 25141276
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Intranasal seasonal influenza vaccine and a TLR-3 agonist, rintatolimod, induced cross-reactive IgA antibody formation against avian H5N1 and H7N9 influenza HA in humans.
    Overton ET; Goepfert PA; Cunningham P; Carter WA; Horvath J; Young D; Strayer DR
    Vaccine; 2014 Sep; 32(42):5490-5. PubMed ID: 25128802
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Broadly protective immunity against divergent influenza viruses by oral co-administration of Lactococcus lactis expressing nucleoprotein adjuvanted with cholera toxin B subunit in mice.
    Lei H; Peng X; Jiao H; Zhao D; Ouyang J
    Microb Cell Fact; 2015 Aug; 14():111. PubMed ID: 26242406
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Functional antibody-dependent cell mediated cytotoxicity (ADCC) responses to vaccine and circulating influenza strains following vaccination.
    Chen X; Sun HY; Lee CY; Rostad CA; Trost J; Abreu RB; Carlock MA; Wilson JR; Gansebom S; Ross TM; Steinhauer DA; Anderson EJ; Anderson LJ
    Virology; 2022 Apr; 569():44-55. PubMed ID: 35255298
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The nucleoprotein of newly emerged H7N9 influenza A virus harbors a unique motif conferring resistance to antiviral human MxA.
    Riegger D; Hai R; Dornfeld D; Mänz B; Leyva-Grado V; Sánchez-Aparicio MT; Albrecht RA; Palese P; Haller O; Schwemmle M; García-Sastre A; Kochs G; Schmolke M
    J Virol; 2015 Feb; 89(4):2241-52. PubMed ID: 25505067
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Stockpiled Avian Influenza A(H7N9) Vaccines Induce Robust, Nonneutralizing Functional Antibodies Against Antigenically Drifted Fifth-Wave A(H7N9) Viruses.
    Zhong W; Levine MZ
    J Infect Dis; 2019 Sep; 220(8):1276-1280. PubMed ID: 31169293
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Assessing the Protective Potential of H1N1 Influenza Virus Hemagglutinin Head and Stalk Antibodies in Humans.
    Christensen SR; Toulmin SA; Griesman T; Lamerato LE; Petrie JG; Martin ET; Monto AS; Hensley SE
    J Virol; 2019 Apr; 93(8):. PubMed ID: 30700610
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Antibody-dependent cell-mediated cytotoxicity against influenza virus-infected cells.
    Hashimoto G; Wright PF; Karzon DT
    J Infect Dis; 1983 Nov; 148(5):785-94. PubMed ID: 6605395
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Imprinted Anti-Hemagglutinin and Anti-Neuraminidase Antibody Responses after Childhood Infections of A(H1N1) and A(H1N1)pdm09 Influenza Viruses.
    Daulagala P; Mann BR; Leung K; Lau EHY; Yung L; Lei R; Nizami SIN; Wu JT; Chiu SS; Daniels RS; Wu NC; Wentworth D; Peiris M; Yen HL
    mBio; 2023 Jun; 14(3):e0008423. PubMed ID: 37070986
    [TBL] [Abstract][Full Text] [Related]  

  • 39. ADCC: An underappreciated correlate of cross-protection against influenza?
    de Vries RD; Hoschler K; Rimmelzwaan GF
    Front Immunol; 2023; 14():1130725. PubMed ID: 36911705
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Development of influenza H7N9 virus like particle (VLP) vaccine: homologous A/Anhui/1/2013 (H7N9) protection and heterologous A/chicken/Jalisco/CPA1/2012 (H7N3) cross-protection in vaccinated mice challenged with H7N9 virus.
    Smith GE; Flyer DC; Raghunandan R; Liu Y; Wei Z; Wu Y; Kpamegan E; Courbron D; Fries LF; Glenn GM
    Vaccine; 2013 Sep; 31(40):4305-13. PubMed ID: 23891795
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.